Related Experiment Video
Updated: Apr 23, 2026
10:32
Development of a Virtual Reality Assessment of Everyday Living Skills
Published on: April 23, 2014
20.2K
Emerging drugs for schizophrenia: an update
Luisa-Sophie Köster1, Maren Carbon, Christoph U Correll
1Technische Universität München, Klinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar , München , Germany.
Expert Opinion on Emerging Drugs
|September 20, 2014
Summary
New schizophrenia treatments targeting negative and cognitive symptoms are needed. Greater innovation may arise from exploring extra-dopaminergic mechanisms and improving research methods for better patient outcomes.
Area of Science:
- Psychiatry and Neuroscience
- Pharmacology
Background:
- Schizophrenia is a severe mental disorder with limited treatment options.
- Current antipsychotics primarily address positive symptoms, leaving negative and cognitive symptoms undertreated.
- Negative and cognitive symptoms significantly impair functional outcomes in schizophrenia patients.
Purpose of the Study:
- To review emerging drug development targets for schizophrenia in Phase II and III clinical trials.
- To discuss the mechanisms of action and clinical results of these novel treatments.
- To identify barriers and summarize the development status of new schizophrenia therapies.
Main Methods:
- Review of current Phase II and III clinical trial data for schizophrenia drug targets.
- Analysis of mechanisms of action for novel therapeutic agents.
- Discussion of challenges in drug development and clinical trial design.
Main Results:
- Antidopaminergic mechanism modifications offer limited improvements for negative symptoms, cognition, and function.
- Emerging treatments show potential but require further validation.
- Significant advancements may depend on exploring non-dopaminergic pathways.
Conclusions:
- Further exploration of extra-dopaminergic mechanisms is crucial for greater innovation.
- Investment in animal models, screening methods, and clinical trial optimization is necessary.
- Stratifying schizophrenia into biologically homogeneous subgroups will enhance treatment development.
Keywords:
agonistantagonistdopaminemechanisms of actionmedicationsnon-dopaminergicpsychosisschizophreniaMore Related Videos
Related Concept Videos
01:28Psychosis and Antipsychotic Drugs: Overview
1.2K
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K
01:28Drug Therapy
442
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
442
01:26Psychosis: Goals of Pharmacotherapy
693
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
693
01:21Antipsychotic Drugs: Typical and Atypical Agents
1.3K
Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
1.3K
01:21Antipsychotic Drugs: Therapeutic Uses and Side Effects
1.2K
Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
1.2K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
2.5K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.5K